Join the Firvanq group to help and get support from people like you.
Firvanq News
Reduced Vancomycin Susceptibility Tied to Poorer C. Diff Outcomes
TUESDAY, April 30, 2024 – Reduced vancomycin susceptibility is impacting clinical responses among adults with Clostridioides difficile (C. difficile) infection, according to a study recently...
Vancomycin May Be Losing Strength Against Common Deadly Infection
FRIDAY, April 26, 2024 – Clostridioides difficile (C. difficile) is a leading cause of illness and death, especially for frail and hospitalized Americans. Now, a new study suggests that the leading...
Extra Antibiotic With Hip, Knee Replacement Won't Prevent Infections: Study
THURSDAY, Oct. 19, 2023 – Millions of people undergo joint replacement surgery every year. To prevent infection, doctors often give them a second antibiotic – but new research suggests this can...
Adding Vancomycin to Cefazolin Prophylaxis Does Not Prevent Surgical Site Infections
WEDNESDAY, Oct. 18, 2023 – The addition of vancomycin to cefazolin prophylaxis is not superior to placebo for prevention of surgical site infections in patients undergoing arthroplasty, according to...
FDA Medwatch Alert: Hospira, Inc. Issues A Voluntary Nationwide Recall For One Lot of Vancomycin Hydrochloride Injection, USP 1.5g/vial, Due To The Presence of Visible Glass Particulates
December 22, 2022 - NEW YORK, NY., Hospira, Inc., a Pfizer company, is voluntarily recalling one lot of Vancomycin Hydrochloride Injection, USP, 1.5 g/vial Single Dose Fliptop Vial, lot 33045BA, to...
FDA Medwatch Alert: Edge Pharma, LLC Issues Voluntary Nationwide Recall of All Drug Products Due to Lack of Sterility Assurance
December 4, 2021 – Colchester, VT, Edge Pharma, LLC is voluntarily recalling all lots of all drugs compounded at Edge Pharma, LLC to the consumer level. All products are being recalled due to process ...
FDA Medwatch Alert: Azurity Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of One Lot of Firvanq (Vancomycin HCl for Oral Solution) 50 mg/mL Kit Due to a Mix-Up of the Diluent
September 08, 2021 – Wilmington, MA, Azurity Pharmaceuticals, Inc. (“Azurity”) is voluntarily recalling one lot of Firvanq (vancomycin hydrochloride for oral solution), Vancomycin 50 mg/mL Kit (“F...
CutisPharma Announces FDA Approval of Firvanq (vancomycin) for Treatment of Clostridium Difficile Associated Diarrhea and Staphylococcus Aureus Colitis
WILMINGTON, Mass. (Jan. 29, 2018) – CutisPharma announced today that the US Food and Drug Administration (FDA) has approved Firvanq (vancomycin hydrochloride) for oral solution, for the treatment of C...
Ask a question
To post your own question to this support group, sign in or create an account.